Edwards Lifesciences raises 2026 sales forecast after second quarter revenue grew 13.6% to $1.74 billion.

Edwards Lifesciences reported second quarter revenue of $1.74 billion and adjusted EPS of $0.78, beating consensus estimates of $1.70 billion and $0.73. Revenue increased 13.6% year-over-year, driven by broad-based growth across its product portfolio.

Key Highlights

• Transcatheter Aortic Valve Replacement (TAVR) sales grew 11.3% to $1.26 billion, benefitting from strong procedure volumes and share gains from a competitor's exit.
• The Transcatheter Mitral and Tricuspid Therapies (TMTT) segment delivered standout growth, with sales increasing 47.3% year-over-year to $195.9 million.
• Full-year 2026 sales guidance was raised to 10-11% constant currency growth, up from 9-11% previously, while reaffirming adjusted EPS guidance of $2.95 to $3.05.